Q32 Bio Inc.
HealthcareNASDAQ:QTTB · NASDAQ Global Market
-$0.06 today
Vol 0.33M · Avg 0.74M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
71.0%
avg -109.3%
ROIC
29.5%
avg -61.6%
ROA
48.3%
avg -41.4%
Analysis
ROE is currently the strongest return metric at 71.0% versus its period average of -109.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jodie Pope Morrison | Chief Executive Officer & Director | $1.00M | — | 50 | $89,104.00 | 0.70% |
Lee H. Kalowski | Chief Financial Officer & President | $792,770.00 | — | 45 | $35,943.00 | 0.28% |
Shelia Violette | Co-founder, Chief Scientific Officer & President of Research | $641,884.00 | — | 65 | $55,569.00 | 0.43% |
David Appugliese | Senior Vice President & Head of People | — | — | — | $16,363.00 | 0.13% |
Maria Marzilli | Chief Business Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$30.00M
Sells
8
$216,604.72
Net Sentiment
+$29.78M
Net buying
Most Active
Kalowski Lee
3 transactions
1–10 of 12
Analysis
Insiders reported 4 buys worth $30.00M and 8 sells worth $216,604.72 over the last 12 months. That adds up to net buying of $29.78M. Kalowski Lee was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +49.9% (10yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +49.9% (10yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$61.03M
Generation Bio Co.
GBIO
$35.98M
SAB Biotherapeutics, Inc.
SABS
$31.83M
Boundless Bio, Inc.
BOLD
$31.67M
Plus Therapeutics, Inc.
PSTV
$12.12M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
Intensity Therapeutics, Inc.
INTS
$6.83M
NextCure, Inc.
NXTC
$5.56M
Iterum Therapeutics plc
ITRM
$1.60M
Who manages QTTB?
Q32 Bio Inc. (QTTB) lists 5 active executives. The top listed executive is Shelia Violette, Co-founder, Chief Scientific Officer & President of Research.
Are QTTB insiders buying or selling?
Recent insider activity shows net buying of $30.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.